Elanco Animal Health (NYSE:ELAN) Insider Rajeev Modi Purchases 4,911 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Rajeev Modi purchased 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $19.78 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The business’s 50 day simple moving average is $23.16 and its two-hundred day simple moving average is $23.31. The stock has a market capitalization of $9.88 billion, a P/E ratio of -39.55, a price-to-earnings-growth ratio of 2.14 and a beta of 1.69. Elanco Animal Health Incorporated has a one year low of $12.40 and a one year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same period in the previous year, the firm earned $0.37 EPS. The business’s quarterly revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently made changes to their positions in the company. Independent Advisor Alliance boosted its position in shares of Elanco Animal Health by 364.5% during the third quarter. Independent Advisor Alliance now owns 98,025 shares of the company’s stock valued at $1,974,000 after purchasing an additional 76,920 shares in the last quarter. State of Michigan Retirement System bought a new stake in shares of Elanco Animal Health during the third quarter valued at approximately $2,383,000. Amalgamated Bank boosted its holdings in Elanco Animal Health by 793.7% in the third quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock worth $4,563,000 after acquiring an additional 201,226 shares in the last quarter. Teachers Retirement System of The State of Kentucky bought a new stake in Elanco Animal Health in the third quarter worth $2,215,000. Finally, JPMorgan Chase & Co. boosted its holdings in Elanco Animal Health by 266.4% in the third quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock worth $38,635,000 after acquiring an additional 1,394,839 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Morgan Stanley boosted their target price on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Leerink Partners boosted their target price on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Finally, Citigroup boosted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.20.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.